Patient Advocates Urge Action on PPRV to Help Fight Rare Disease

Why It Matters

Without PPRV, biotech firms lose a critical financial incentive, risking abandonment of pediatric rare‑disease programs and delaying life‑saving treatments for children.

Key Takeaways

• 63 vouchers awarded since 2012 for 47 rare pediatric diseases
• Program expired 2024; House passed reauthorization bill Dec 1
• Vouchers enable faster FDA review or generate hundreds‑million‑dollar sales
• Prior to PPRV, only four of those diseases had treatments
• Advocates urge Senate “hotline” vote before year‑end

Pulse Analysis

The Pediatric Priority Review Voucher (PPRV) was introduced by Congress in 2012 to spur development of therapies for ultra‑rare pediatric diseases. Under the program, the FDA awards a transferable voucher to any company that secures approval for a drug that treats a qualifying rare condition. The voucher can be sold for up to $300 million or used to accelerate review of a subsequent product, effectively offsetting the high cost of small‑population trials. A recent NORD analysis shows 63 vouchers have been granted for 47 distinct diseases, raising the number of approved treatments from four to dozens and saving countless young lives.

The program’s authorization lapsed in 2024, prompting a coordinated push from patient groups, biotech trade association BIO, and lawmakers. The House passed the Mikaela Naylon Give Kids a Chance Act on Dec. 1, reinstating the voucher framework, and advocates are now lobbying the Senate for a rapid “hotline” vote before the holiday recess. Speakers at BIO’s Patient Advocacy Coffee Chat highlighted personal stories—from the Firefly Fund’s founders to the Muscular Dystrophy Association—to illustrate what would be lost if the voucher market disappears. The bipartisan nature of the bill, combined with its zero cost to taxpayers, makes it a compelling target for swift legislative action.

For biotech firms, the PPRV represents a rare source of capital that can bridge the gap between scientific promise and commercial viability. Small‑ and mid‑size companies, which often lack the cash reserves of large pharma, rely on voucher sales to fund ongoing trials or to attract investors. Reauthorizing the program therefore sustains a pipeline of pediatric rare‑disease candidates, encouraging innovation and reducing time‑to‑market for life‑saving drugs. Patients and families stand to benefit from an expanded therapeutic arsenal, while the broader healthcare system may see lower long‑term costs as early interventions prevent severe disability. Continued support for PPRV could cement the United States’ leadership in rare‑disease research.